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TNF-αDecoy receptor 3 (DcR3) is a soluble receptor of Fas ligand (FasL), LIGHT (TNFSF14) and TNF-like molecule 1A
(TL1A) and plays pleiotropic roles in many inﬂammatory and autoimmune disorders and malignant diseases.
In cutaneous biology, DcR3 is expressed in primary human epidermal keratinocytes and is upregulated in
skin lesions in psoriasis, which is characterized by chronic inﬂammation and angiogenesis. However, the
regulatory mechanisms of DcR3 over-expression in skin lesions of psoriasis are unknown. Here, we demon-
strate that DcR3 can be detected in both dermal blood vessels and epidermal layers of psoriatic skin lesions.
Analysis of serum samples showed that DcR3 was elevated, but FasL was downregulated in psoriatic patients
compared with normal individuals. Additional cell studies revealed a central role of epidermal growth factor
receptor (EGFR) in controlling the basal expression of DcR3 in keratinocytes. Activation of EGFR by epidermal
growth factor (EGF) and transforming growth factor (TGF)-α strikingly upregulated DcR3 production.
TNF-α enhanced DcR3 expression in both keratinocytes and endothelial cells compared with various inﬂam-
matory cytokines involved in psoriasis. Additionally, TNF-α-enhanced DcR3 expression in keratinocytes was
inhibited when EGFR was knocked down or EGFR inhibitor was used. The NF-κB pathway was critically
involved in the molecular mechanisms underlying the action of EGFR and inﬂammatory cytokines. Collectively,
the novel regulatory mechanisms of DcR3 expression in psoriasis, particularly in keratinocytes and endothelial
cells, provides new insight into the pathogenesis of psoriasis and may also contribute to the understanding of
other diseases that involve DcR3 overexpression.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Psoriasis is a common and chronic inﬂammatory disease with a
prevalence of 1–3% worldwide. It typically involves various sites on
the skin and may cause nail lesions and arthropathy [1,2]. Many
predisposing genetic and environmental factors contribute to the
onset and progress of psoriatic lesions. Genetic and immunological
studies have noted the critical role of cytokine networks in the path-
ogenesis of psoriasis [3,4]. Rather than being a pure T-helper 1 (TH1)
mediated disease, recent studies reveal that TH17 cells play an indis-
pensable role in the disease process. The central cytokines in the
TH17 response, such as IL-17, IL-22 and IL-23, are responsible for the
pathologic phenotypes of psoriatic skin lesions [2,5,6]. Recently,cology, College of Medicine,
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l rights reserved.success in the treatment of psoriasis using biologic agents that neu-
tralize the actions of TNF-α and IL-23 strongly supports the proposed
immunopathogenic mechanisms of psoriasis [2,7]. In addition to the
critical roles of the local cytokine milieu in the pathogenesis of psori-
asis, reciprocal regulation of signals from T cells, dendritic cells and
epidermal keratinocytes orchestrates the complicated process of
psoriatic plaque formation,which is characterized by hyperproliferation
of epidermal keratinocytes, aberrant differentiation of keratinocytes,
angiogenesis and inﬁltration of distinct types of inﬂammatory cells
[5,8].
The epidermal growth factor (EGF) receptor system regulatesmul-
tiple cellular functions such as proliferation, migration and inﬂamma-
tion [9]. Among the four erythroblastic leukemia viral (v-erb-b)
oncogene homolog (ErbB) receptors, ErbB1 (also known as EGFR),
ErbB2, and ErbB3 are expressed in human skin [10]. Many types of
EGFR ligands have been identiﬁed, and epidermal keratinocytes are
able to produce transforming growth factor (TGF)-α, amphiregulin,
heparin binding (HB)-EGF, and epiregulin. Under basal conditions,
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nocytes [11,12]. The critical roles of EGFR signaling in cutaneous
inﬂammation and wound healing process have been widely investi-
gated [11]. In psoriasis, overexpression of TGF-α in psoriatic epidermis
has been reported [13], and transgenic expression of the amphiregulin
gene can induce a psoriasis-like phenotype [14]. Many studies also
indicate that, unlike in normal skin, the expression and activity of
EGFR are retained in the upper layer of the psoriatic epidermis
[15,16]. In addition, vitamin D3 derivative, an anti-psoriatic agent,
has also been reported to inhibit the expression of EGFR in human
epidermal keratinocytes [17].
Decoy receptor 3 (DcR3) is a member of the tumor necrosis factor
receptor (TNFR) superfamily, which is also known as TNFR superfamily
6B (TNFRSF6B)/M68/TR6. DcR3 is a soluble factor lacking a transmem-
brane domain, which exerts a decoy function, including neutralizing
Fas ligand (FasL/CD95L/TNFSF6), LIGHT (lymphotoxin-like, exhibits
inducible expression, and competes with herpes simplex virus (HSV)
glycoprotein D for HVEM), TNFSF14, and TNF-like molecule 1A (TL1A/
VEGI/TNFSF15) to inhibit apoptosis and promote angiogenesis [18,19].
DcR3 also plays various non-decoy functions, such as modulating den-
dritic cell differentiation to TH2 polarization [20], driving macrophages
to an M2 phenotype [21,22], inducing osteoclast differentiation [23],
promoting monocyte adhesion [24], and inhibiting MHC-II expression
via epigenetic regulation [22]. In earlier studies, DcR3 was reported to
be elevated in serum or tissue samples of different cancers including
lung, stomach, colon, pancreas and ovarian cancers and was regarded
as a biomarker of cancer progression [18,19]. In addition to its roles in
tumorigenesis, recent studies have also demonstrated up-regulation
of DcR3 in many autoimmune and inﬂammatory diseases including
silicosis [25], Crohn's disease [26], systemic lupus erythematosus [27],
rheumatoid arthritis [28], and acute respiratory distress syndrome [29].
DcR3 is constitutively expressed in primary human epidermal
keratinocytes and is downregulated by UVB irradiation [30]. A clinical
study reported the elevation of serum DcR3 in patients with atopic
dermatitis [31]. Furthermore, a recent investigation has revealed
that DcR3 is actually over-expressed in the lesional epidermal layers
of psoriasis [32]. Based on our previous investigation and other
reports, we conclude that DcR3 is critically involved in the inﬂamma-
tory response and is able to promote angiogenic processes [18,33,34].
Thus, it seems reasonable to ﬁnd the up-regulation of DcR3 in psori-
atic skin, which is characterized by chronic inﬂammation and promi-
nent angiogenesis. However, studies investigating how DcR3 can be
regulated in epidermal keratinocytes and psoriasis are still limited.
Here, we investigate the expression of DcR3 in skin lesions and
serum samples of psoriatic patients, and explore the regulatory
mechanisms underlying DcR3 expression in epidermal keratinocytes,
which can further our understanding of psoriatic pathogenesis.
2. Materials and methods
2.1. Patient samples
For tissue samples, parafﬁn-embedded skin specimens from psori-
atic patients and non-psoriatic subjects were collected retrospectively
for immunohistochemical studies. For serum samples from psoriatic
patients, biologic-naïve patients who had not received phototherapy
or other systemic anti-psoriatics treatments for at least one month
were selected. The psoriasis area and severity index (PASI) scores of
psoriatic patients were evaluated at our outpatient department at
the time of serum collection. For control serum samples, adult volun-
teers who visited our outpatient department or received health
checkups during the same period were selected. For both the psoriatic
and control groups, subjects with known non-psoriatic inﬂammatory
disorders, infectious diseases or malignancies were excluded from
this study. The collected serum samples were stored at −80 °C until
the ELISA analysis was performed.2.2. Immunohistochemical staining
For the immunohistochemical studies, formalin ﬁxed and parafﬁn-
embedded tissue sections were deparafﬁnized and hydrated. Steam
heat antigen retrieval was performed with Trilogy retrieval buffer
(Cell Marque Cooperation, Austin, TX, USA) for 20 min. The slides
were then incubated with primary antibodies against DcR3 (Abnova,
Taipei, Taiwan) at 4 °C overnight. The antigen was then detected
using the iVIEWTM DAB Detection Kit (VENTANA, Tucson, AZ, USA)
according to the manufacturer's instructions. The specimens were
then counter-stained with hematoxylin [35].
2.3. Cell culture
Normal human epidermal keratinocytes (NHEKs) were obtained
from normal adult human foreskin [36]. Brieﬂy, the skin was divid-
ed and incubated in 1% protease (Sigma-Aldrich, MO, USA) over-
night at 4 °C to separate the epidermis from the dermis. The
keratinocytes were disaggregated into a single-cell suspension in
serum-free Dulbecco's modiﬁed Eagle's medium (DMEM) and
centrifuged. Isolated keratinocytes were cultured in Keratinocyte-SFM
(Gibco BRL/Invitrogen, Carlsbad, CA, USA) supplemented with rEGF
(0.1–0.2 ng/ml), bovine pituitary extract (20–30 μg/ml), and 1% peni-
cillin/streptomycin in a humidiﬁed atmosphere at 37 °C and 5% CO2.
The second to fourth passage cells were used in experiments. For
human umbilical vein endothelial cells (HUVECs), cryopreserved cells
were purchased from ScienCellTM Research Laboratories (ScienCellTM,
Carlsbad, CA, USA). HUVECs were cultured in endothelial cell medium
(ScienCellTM, Carlsbad, CA, USA) supplemented with 5% fetal bovine
serum in a humidiﬁed atmosphere at 37 °C and 5% CO2.
2.4. Reagents
Antibodies directed against JNK1, ERK2, p38, EGFR, IKKα/β and
horseradish peroxidase-coupled second antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
for phosphorylated-JNK, -ERK, and -p38, -EGFR (Y1068), -IKKα/β
(S176/177) were purchased from Cell Signaling Technology (Beverly,
MA, USA). An antibody against β-actin was purchased from Upstate
Biotechnology (Charlottesville, VA, USA). The enhanced chemilumi-
nescence reagent was purchased from Perkin Elmer (Wellesley, MA,
USA). Recombinant human TNF-α, interleukin (IL)-1α, IL-1β, IL-8,
IL-17A, IL-19, IL-20, IL-22, EGF, and TGF-α were purchased from
PeproTech (Rocky Hill, NJ, USA). Geﬁtinib was purchased from
Cayman Chemical Company (Ann Arbor, MI, USA). BMS-345541,
U0126, SB203580 and SP600125 were purchased from Calbiochem
(San Diego, CA, USA).
2.5. Small interference RNA (siRNA) transfection
siRNA experiments were performed using ON-TARGET plus
SMARTpool siRNA for human EGFR and non-targeting siRNA as a con-
trol (Thermo Fisher Scientiﬁc, Lafayette, CO, USA). NHEKs were
transfected with 100 nM siRNA by DharmaFECT Transfection Reagents
at approximately 50% conﬂuence following the manufacturer's instruc-
tions. Cells were collected at the indicated time points.
2.6. Western blotting
After treatment with the indicated drugs, cells were harvested and
equal amounts of soluble protein were loaded and electrophoresed
on SDS-PAGE, and then transferred to Immobilon-P membranes
(Millipore, Billerica, MA, USA). Speciﬁc protein bands were detected
with the enhanced chemiluminescence detection reagent.
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After stimulation, cells were harvested and subjected to reverse
transcription with an RT-PCR kit (Promega, Heidelberg, Germany).
PCR was performed in 96-well plates using FastStart SYBR Green
Master Mix (Roche, Diagnostics, Indianapolis, IN, USA) and quantiﬁed
by an ABI Prism 7900 (Applied Biosystems, CA, USA). mRNA expres-
sion was normalized to the housekeeping gene cyclophilin A [36].
Primers for DcR3 (NM_003823.3) were designed by Primer Express
Software (Applied Biosystems, CA, USA).
2.8. ELISA assay
For the detection of human serum samples, commercial ELISA kits
for LIGHT, FasL, DcR3 (R&D Systems, Minneapolis, MN, USA) and TL1A
(PeproTech, Rocky Hill, NJ, USA) were used to determine the serum
levels according to themanufacturer's instructions. To assay cell culture
supernatants, cell culture media was collected at various timepoints
after the indicated treatment.
2.9. NF-κB luciferase assay
NHEKs were cotransfected with an NF-κB reporter plasmid and a
β-galactosidase expression vector (pSVlacZ) using the Lipofectamine
2000 Transfection reagent (Invitrogen). Twenty-four hours after
transfection, cells were treated and collected at the indicated time
points. Then, cells were washed and lysed in a reporter lysis buffer
(Promega). Subsequently, the lysates were reacted with a commercial
luciferase substrate provided in the luciferase assay system kit
(Promega), and measured using a microplate luminometer (Packard,
Meriden, CT, USA). Luciferase activity values were normalized to
transfection efﬁciency monitored by β-galactosidase expression and
presented as the percentage of luciferase activity of the control
group. The NF-κB reporter plasmid containing three κB binding sites
(pGL2-ELMA-luciferase) was provided by Dr. S.-L, Hsieh (Yang-Ming
University, Taipei, Taiwan).
2.10. Statistical analysis
SPSS 18.0 software was used for statistical analysis of serum
samples. For normally distributed analytes (LIGHT and FasL), the
data were analyzed using a T-test to compare the means of psoriatic
and non-psoriatic samples. For non-normally distributed analytes
(TL1A and DcR3), the data were analyzed using the non-parametric
Mann–Whitney U-test to analyze the difference between the psoriatic
and non-psoriatic samples. Correlations between different markers
were analyzed using Spearman's correlation. Statistical signiﬁcance
was assumed for a P-value of less than 0.05. For cell studies, data
were expressed as the mean ± S.E.M. and Student's t-test was used
to assess the statistical signiﬁcance of the differences. A P value b 0.05
was considered statistically signiﬁcant.
2.11. Study approval
As for the collection of human samples including adult foreskin,
serum and biopsy specimens, written consent was obtained from
each donor before experiments were performed. The experiments
were conducted according to the Declaration of Helsinki Principles
and approved by the ethical committee of Mackay Memorial Hospital.
3. Results
3.1. Up-regulation of DcR3 in psoriatic skin lesions
Accumulating evidence suggests that DcR3 is involved in various
inﬂammatory disorders in addition to its roles in tumorigenesis[18]. In Crohn's disease, which shares similar immune features with
psoriasis [37] and is often co-morbid with psoriasis [38], DcR3 is
over-expressed in the lesional intestinal epithelium [26]. We thus
wondered if DcR3 also plays a role in inﬂammatory skin diseases
such as psoriasis. To investigate the role of DcR3 in psoriasis, we
examined the expression pattern of DcR3 in biopsy specimens of
psoriatic skin. A total of 23 samples of psoriatic skin lesions and 20
samples of non-psoriatic skin lesions were collected for immuno-
histochemical studies. For the psoriatic specimens, positive staining
of DcR3 in the epidermis was detected in 20 samples, despite varying
staining intensities. However, in the non-psoriatic samples, DcR3 was
only detected in 2 cases. As shown in Fig. 1A and B, DcR3 was barely
detected in normal skin but was obviously expressed in the upper
epidermis of psoriatic skin lesions. In some patients, DcR3 was
detected around the area of a spongiform pustule of Kogoj, a charac-
teristic pattern of epidermal spongiosis with prominent inﬁltration of
inﬂammatory cells such as neutrophils, and could also be found be-
neath areas of parakeratosis (Fig. 1A). Compared with psoriatic skin
lesions, DcR3 was barely detected in the lesional epidermal layers
of other inﬂammatory dermatoses, such as cutaneous lupus erythe-
matosus and lichen planus (Fig. 1B). Another important pathologic
feature was the expression of DcR3 in the endothelial cells of vessels
located in the upper dermis of psoriasis. Dermal vessels with detect-
able DcR3 staining could be found in 19 psoriatic samples compared
with only 2 non-psoriatic samples. We further stained nearby tissue
sections with CD31 to demonstrate the distribution of dermal vessels
(Fig. 1C). Comparing DcR3 staining with CD31 staining, we found the
expression of DcR3 was limited to the endothelial cells localized in
the upper dermal vessels and was not distributed in all of dermal
vessels in psoriatic lesions.
3.2. Up-regulation of DcR3 and down-regulation of FasL in the serum of
psoriatic patients
Previous studies have demonstrated that the serum level of DcR3
is usually low or barely detected in normal people and is elevated in
patients with autoimmune or malignant diseases [26,39–41]. We
found that DcR3 was over-expressed in psoriatic skin, so we further
evaluated whether DcR3 was also increased in the serum of psoriatic
patients compared with normal subjects. Because of the possible
pathological intervention stemming from a molecular interaction
between DcR3 and its three corresponding ligands, including LIGHT,
FasL and TL1A, we also examined the serum levels of these ligands
and further explored any possible correlation between these
interacting molecules. Serum samples from 39 patients and 26
healthy control individuals were collected for analysis and the clinical
disease severity of psoriatic patients was measured by PASI score
when blood samples were collected. As shown in Fig. 2A and B, we
did not ﬁnd any signiﬁcant differences of the serum levels of LIGHT
and TL1A between patients and controls. In Fig. 2C, the serum level
of FasL in normal subjects was signiﬁcantly higher than in psoriatic
patients. The serum level of DcR3 in normal subjects was mostly
undetectable or relatively low and was elevated in patients
(Fig. 2D). In the control group, DcR3 was detectable in 6/26 (23%)
subjects. In the psoriatic group, DcR3 was detectable in 18/39 (46%)
patients. The correlation between the DcR3 serum level and the
PASI score was not statistically signiﬁcant (p = 0.076) (Fig. 2E). We
further explored the possible relationship between DcR3 and its
ligands. As shown in Fig. 2F, the correlation between DcR3 and FasL
serum levels in psoriatic patients was not statistically signiﬁcant
(p = 0.052). However, because the p value is close to 0.05, and anal-
ysis for serum DcR3 or FasL showed the difference between psoriatic
patients and normal individuals was statistically signiﬁcant (Fig. 2C
and D), it seems reasonable to hypothesize that DcR3 expression
could be inversely correlated with FasL expression in the serum of
psoriatic patients. In Fig. 2G and H, serum levels of DcR3 were also
Fig. 1. Expression of DcR3 in the epidermis and dermal vessels of psoriatic skin lesions. (A) Immunohistochemical staining indicated the expression of DcR3 (brownish color) in the
upper layers of epidermis, around a spongiform pustule of Kogoj (patient 3) and beneath the parakeratotic corneal layers (patient 4, arrows). (B) Immunohistochemical staining for
DcR3 was also performed in skin specimens of normal subjects, cutaneous lupus erythematosus and lichen planus. (C) Detection of DcR3 staining in the vessels of the upper dermis
of psoriatic lesions. CD31 staining on a nearby tissue section was also performed. Bar = 200 μm.
1541N.-L. Wu et al. / Biochimica et Biophysica Acta 1832 (2013) 1538–1548not correlated with TL1A or LIGHT serum levels. Nevertheless we
found TL1A was inversely correlated with LIGHT in the patient
group, although both TL1A and LIGHT serum levels were not changed
in psoriatic patients compared with controls (Fig. 2I).
3.3. EGF and TGF-α promote the production of DcR3 in epidermal
keratinocytes
Because TGF-α and EGFR are overexpressed in the psoriatic
epidermis [13,15], we wondered if EGFR activation could affect the
expression of DcR3 in keratinocytes. When NHEKs were starved in
basal culture media without supplementary growth factors, the
expression of DcR3 could still be constitutively detected, but was
lower than that in complete media, which contains a low concentra-
tion of EGF (data not shown). After treatment of starved NHEKs
with EGF or TGF-α, mRNA expression of DcR3 was prominently
enhanced in a time and dose-dependent manners (Fig. 3A and C).
When treating NHEKs with 100 ng/ml EGF or TGF-α for 24 h, a
2-fold induction of soluble DcR3 expression was seen (Fig. 3B and
D). With similar treatments, we could also detect a 2- to 3-fold induc-
tion of intracellular DcR3 expression in NHEKs (Fig. 3E). Theseﬁndings suggest EGFR signaling plays an important role in the regu-
lation of DcR3 expression in human epidermal keratinocytes.
3.4. The EGFR/NF-κB signaling pathway mediates the expression of DcR3
in epidermal keratinocytes
To evaluate the role of EGFR on DcR3 expression in NHEKs, we
tried to knock down EGFR in NHEKs. Three days after knocking
down EGFR, the mRNA expression of DcR3 was prominently
suppressed (Fig. 4A). ELISA further conﬁrmed that soluble DcR3 re-
leased from NHEK was inhibited following knockdown of EGFR
(Fig. 4B). Similarly, the basal expression of intracellular DcR3 was
also severely decreased (Fig. 4C). Thus, under basal condition without
additional stimuli, EGFR signaling controls the basal expression of
DcR3 in primary human epidermal keratinocytes. Furthermore,
when checking EGFR mediated signaling in NHEKs, both EGF and
TGF-α could activate EGFR, which was accompanied by down-
regulation of the receptor, and activation of downstream signaling
molecules including IKKα/β, ERK1/2, p38 and JNK (Fig. 4D). Using
an NF-κB luciferase assay, we conﬁrmed that both EGF and TGF-α
could activate the NF-κB pathway (Fig. 4E). To explore the regulation
Fig. 2. Serum levels of LIGHT, TL1A, FasL and DcR3 in psoriatic patients and non-psoriatic normal donors. (A–D) Serum samples were collected from psoriatic patients and
non-psoriatic controls. ELISA analysis for the serum concentrations of LIGHT, TL1A, FasL and DcR3 were performed. For LIGHT and FasL, a T test was performed to analyze the
difference between the patient and control group. For TL1A and DcR3, a Mann–Whitney U-test was applied. The median concentrations of each group and p value were presented.
(E–I) Spearman's correlation was used to analyze any possible correlation between different parameters. Spearman's correlation coefﬁcients γ and p values are presented.
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logic inhibitors of IKKα/β (BMS-345541), ERK1/2 (U0126), p38
(SB203580) and JNK (SP600125) to evaluate molecular mechanisms.
As shown in Fig. 4F, treatment with the IKK inhibitor, BMS-345541,
reduced expression of soluble DcR3 induced by EGF and TGF-α. More-
over, the JNK inhibitor (SP600125) also exerted a similar inhibition of
DcR3, but the effect was milder than BMS-345541. Inhibitors of p38
(SB203580) and ERK (U0126) had no effect. Therefore, the EGFR/
IKK pathway regulates the expression of soluble DcR3 in epidermal
keratinocytes. To further evaluate the relationship between JNK and
NF-κB activation, we checked the activation of JNK by EGF and
TGF-α after pretreatment with BMS-345541 (Fig. 4G), and also used
NF-κB luciferase assay to investigate the NF-κB activation after pre-
treatment with JNK inhibitor, SP600125 (Fig. 4H). The results indicate
the JNK and NF-κB pathways are independent of each other in the
regulation of DcR3 expression upon EGFR activation.
3.5. TNF-α enhances DcR3 expression in epidermal keratinocytes via an
NF-κB dependent pathway
Cytokines and chemokines involved in TH1/TH17 immune responses
are regarded as the central pathogenic factor in psoriasis [5]. Thus, we
investigated the effects of various inﬂammatory cytokines involved in
psoriasis on DcR3 expression in NHEKs. When NHEKs were stimulated
with these cytokines, TNF-α caused the most prominent induction ofintracellular and soluble DcR3 in NHEKs. In addition, IL-1β and IL-22
could also enhance DcR3 expression in NHEKs to a lesser extent
(Fig. 5A).We further conﬁrmed that TNF-α could induce the expression
of DcR3 mRNA, soluble and intracellular DcR3 in a dose- and
time-dependent manner (Fig. 5B,C, and D). Because the NF-κB pathway
mediated EGFR-regulated DcR3 expression (Fig. 4), we evaluated
TNF-α and IL-1β signaling using the NF-κB luciferase activity assay. As
shown in Fig. 5E, TNF-α caused a more prominent induction of
luciferase activity than IL-1β. By pre-treating NHEKswith the IKK inhib-
itor, BMS-345541, the enhancement of DcR3 by TNF-α and IL-1β was
signiﬁcantly reduced (Fig. 5F), which indicates the important role of
the NF-κB pathway in the regulation of DcR3 expression. In addition,
because of the critical role of EGFR signaling in the regulation of DcR3
expression (Fig. 4), we further evaluated the roles of EGFR signaling
in TNF-α-induced DcR3 expression. As shown in Fig. 5G, TNF-α could
activate EGFR in keratinocytes to some extent. After knocking down
EGFR or inhibiting EGFR kinase activity by geﬁtinib, the TNF-α-
induced intracellular and soluble DcR3 expression were obviously
reduced (Fig. 5H and I). These data suggest DcR3 expression induced
by TNF-α can be mediated by EGFR activation.
3.6. TNF-α induces DcR3 production in human endothelial cells
DcR3 is detected in endothelial cells of the upper dermis in psori-
atic lesions (Fig. 1), where inﬂammatory cells typically inﬁltrate [2].
Fig. 3. DcR3 expression in keratinocytes is increased by EGF and TGF-α. (A) After starvation in media without supplementary growth factors for 48 h, NHEKs were stimulated with
EGF for 6,12, 24 h or EGF at different concentrations. Quantitative real-time RT-PCR was performed to assay DcR3 mRNA expression. (B) With similar treatments, the levels of
soluble DcR3 were determined by ELISA. (C, D) TGF-α was used to assay the expression of DcR3 mRNA and soluble DcR3 in NHEKs. *p b 0.05 (mean ± S.E.M. n = 3) compared
with control. (E) Western blotting was used to evaluate the expression of intracellular DcR3 in NHEKs after EGF or TGF-α treatment.
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expression in endothelial cells using human umbilical vein endotheli-
al cells (HUVECs). Among the various cytokines tested, TNF-α caused
the most prominent induction of intracellular and soluble DcR3
expression in HUVECs, and IL-1β also mildly promoted DcR3 produc-
tion (Fig. 6A). We further conﬁrmed that TNF-α could dose- and
time-dependently induce the expression of DcR3 mRNA, soluble and
intracellular DcR3 in HUVECs (Fig. 6B, C and D). That suggests that,
in addition to over-expression of DcR3 in psoriatic keratinocytes,
DcR3 can also be induced in endothelial cells, and may contribute to
the pathogenesis of psoriasis.
4. Discussion
Previous reports have demonstrated that DcR3 can attenuate the
TH1-mediated immune response but drive the TH2 immune reac-
tion [20,42]. Recent investigations further revealed DcR3 is able tosuppress the TH17-mediated immune reaction [43,44]. Thus, it
seems that up-regulation of DcR3 can be detected in TH2-mediated
diseases such as atopic dermatitis [31]. However, a recent study of
Crohn's disease, which is mainly mediated by TH1/TH17 immune re-
sponses [37,45], showed that DcR3 was detected in lesional intestinal
epithelial cells and up-regulated in the serum of patients, particularly
those with high disease activity [26]. Interestingly, over-expression of
DcR3 in lesional skin of psoriasis was also reported recently [32]. Like-
wise, we found that DcR3 was over-expressed in the lesional skin of
psoriasis and further demonstrated that DcR3 serum levels were
higher in psoriatic patients when compared with normal subjects.
Consequently, despite the immunomodulatory roles DcR3 in sup-
pressing TH1/TH17 immune responses, DcR3 can persist in predomi-
nantly TH1/TH17-mediated diseases such as psoriasis and Crohn's
disease. Further studies are necessary to elucidate whether upreg-
ulated serum DcR3 is a compensatory phenomenon in other diseases
with prominent TH1/TH17 immune responses and/or actually plays a
Fig. 4. Downstream signaling of the EGFR is required for DcR3 expression in keratinocytes. (A) Three days after knocking down EGFR, quantitative real-time PCR was performed to
detect DcR3 mRNA expression in NHEKs. (B) Similar to (A), ELISA was used to evaluate soluble DcR3 production in NHEKs after EGFR knockdown. (C) Western blotting was used to
determine the expression of intracellular DcR3 in NHEKs. (D) After starvation in media without supplementary growth factors for 48 h, EGF and TGF-αwere used to stimulate EGFR
in NEHKs. The phosphorylation of EGFR (Y1068), IKKα/β (S176/177), ERK, p38 and JNK were determined. (E) NHEKs transfected with an NF-κB reporter plasmid were treated with
EGF and TGF-α for 4 h. Cell lysates were collected for the measurement of relative luciferase activity. (F) After pretreatment with SB203580 (2 μM), U0126 (1 μM), SP600125
(2 μM), BMS-345541(3 μM) for 30 min, NHEKs were treated with EGF or TGF-α for 24 h. ELISA was performed to measure the amount of soluble DcR3. (G) After pretreatment
with BMS-345541(3 μM) for 30 min, NHEKs were treated with EGF (100 ng/ml) or TGF-α (100 ng/ml). The phosphorylation of JNK was determined. (H) Similar to (E), after
pretreatment with SP600125 (2 μM), the relative NF-κB luciferase activity was measured. *p b 0.05 (mean ± S.E.M. n = 3).
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angiogenesis. Furthermore, it is also important to investigate the
regulatory mechanisms of DcR3 expression in various immunocytes
to clarify other source(s) of soluble DcR3 in the circulation of psoriatic
patients in addition to epidermal keratinocytes. In addition, while the
correlation between PASI scores and serum DcR3 of psoriatic patients
was not statistically signiﬁcant, the p value was quite small (0.076).Previous reports have also shown that serum levels of many cytokines
involved in psoriasis may not be correlated with scores of disease
activity [46,47]. Consequently, based on this study, a large-scale clin-
ical study is needed to further analyze the clinical signiﬁcance of
circulating DcR3 in psoriasis. Another interesting ﬁnding in our serum
study is that the serum level of FasL in psoriatic patients is suppressed
compared to normal individuals. Similarly, a study of Crohn's disease
Fig. 5. Inﬂammatory cytokines promote DcR3 expression in keratinocytes. (A) NHEKs were stimulated with the indicated cytokines for 24 h. ELISA and western blotting were
performed to detect soluble and intracellular DcR3, respectively. (B) NHEKs were treated with TNF-α (100 ng/ml) for 6, 12, 24 h or TNF-α at different concentrations for 24 h.
Quantitative real-time RT-PCR was performed to evaluate changes in DcR3 mRNA. (C and D) With similar treatments as in (B), ELISA and western blotting were applied.
(E) NHEKs transfected with an NF-κB reporter plasmid were treated with TNF-α and IL-1β for 6 h. Cell lysates were collected for measurement of relative luciferase activity.
(F) After treatment with BMS-345541(BMS, 3 μM) for 30 min, NHEKs were treated with TNF-α or IL-1β for 24 h. Then, the amount of soluble DcR3 was determined by ELISA.
(G) NHEKs were treated with TNF-α (100 ng/ml) for 15 min, 30 min and 1 h. Then the phosphorylation of EGFR (Y1068) was determined. (H and I) Two days after knocking
down EGFR or after pretreatment with geﬁtinib (3 μM) for 30 min, NHEKs were treated with TNF-α (100 ng/ml) for 24 h. Then intracellular DcR3 was determined by western blot-
ting. (I) Similar to (H), ELISA was performed to evaluate the soluble DcR3 production in NHEKs. *p b 0.05 (mean ± S.E.M. n = 3).
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epithelial tissue, although the serum levels of FasL were not mea-
sured [26]. To date, the apoptotic and non-apoptotic actions of FasL
in the immune system have been widely investigated [48]. Thus,
together with over-expression of DcR3 in psoriatic skin and serum,
downregulation of FasL in psoriatic serummay contribute to a reduc-
tion of apoptosis of immune cells, such as T lymphocytes, because
FasL is pro-apoptotic and DcR3 can be anti-apoptotic. However,
further exploration is needed to unravel other biologic actions ofFasL in psoriasis and to further elucidate the balance between FasL
and DcR3 in inﬂammatory diseases.
Hyperproliferation of epidermal keratinocytes with shortening of
cell cycles plays a central role in the thickening of psoriatic plaques
[3]. Earlier studies have demonstrated overexpression of TGF-α, an
EGFR ligand, in psoriasis [13]. The expression and activity of EGFR
are still retained in the uppermost layers of the psoriatic epidermis
compared with normal skin [15]. Our results demonstrated EGF and
TGF-α can positively regulate the DcR3 expression in keratinocytes,
Fig. 6. TNF-α induces DcR3 expression in endothelial cells. (A) Similar to Fig. 5, HUVECs were stimulated with the indicated cytokines for 24 h. ELISA and Western blotting were
performed to detect soluble and intracellular DcR3, respectively. (B) HUVECs were treated with TNF-α (30 ng/ml) for 6, 12, 24 h or TNF-α at different concentrations (10, 30,
100 ng/ml) for 24 h. The change in DcR3 mRNA was measured by quantitative real-time RT-PCR. (C and D) With similar treatments, soluble and intracellular DcR3 were detected
by ELISA and western blot, respectively. *p b 0.05 (mean ± S.E.M. n = 3).
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Moreover, previous reports have revealed TNF-α can activate EGFR
signaling or induce EGFR expression [49–52], and our result also
showed TNF-α could activate EGFR in epidermal keratinocytes. Fur-
thermore, TNF-α-induced DcR3 expression in keratinocytes was
suppressed by knockdown of EGFR or inhibition of EGFR kinase activ-
ity using geﬁtinib, which suggests EGFR signaling is really required
for DcR3 expression. This regulatory pattern is not only important
for the pathogenesis of psoriasis but also possibly signiﬁcant for the
carcinogenesis of epithelial tumors because both overexpression of
DcR3 and over-activation of EGFR are reported in many epithelial
malignancies [9,18]. Furthermore, it would be interesting to evaluate
whether anti-EGFR agents can inhibit DcR3 expression in tumor cells,
and if the therapeutic effects of anti-EGFR agents in cancer treatment
are also partially due to the suppression of DcR3 expression. In addi-
tion, because previous studies reported that the NF-κB pathway can
regulate DcR3 expression [53,54], and NF-κB can be activated after
triggering EGFR in some cell types [55,56], it is not surprising that
we found that EGFR signaling led to activation of IKK/NF-κB in epi-
dermal keratinocytes. We also showed that the JNK pathway could
regulate DcR3 expression. This pathway is similar to the pathway
identiﬁed by a previous study about intestinal epithelia [54].
Our pathologic data indicated that DcR3 is present in epidermal
keratinocytes around the sites of prominent inﬂammation or in the
upper epidermis, where severe inﬂammation typically occurs. Thus
it is reasonable to hypothesize that over-expression of DcR3 in psori-
atic epidermal keratinocytes could be induced by inﬂammatory cyto-
kines. As shown in Fig. 5, TNF-α could promote the expression
of soluble and cytosolic DcR3 in keratinocytes. Similarly, in Crohn's
disease, epithelial cells also exhibit strong DcR3 expression in the
vicinity of obvious inﬂammation. Up-regulation of DcR3 expres-
sion in colon cancer HCT116 cells in response to TNF-α was alsodemonstrated [26]. In addition, a previous report showed UVB irradi-
ation could suppress DcR3 expression in epidermal keratinocytes
[30]. UVB phototherapy is a well-recognized treatment for psoriasis
[7] and our ﬁndings suggest that the effect of UVB on psoriasis may be
partially mediated by a reduction of DcR3 expression in psoriatic
skin. Furthermore, it is intriguing to evaluate whether current anti-
psoriatics such as corticosteroid and vitamin D3 analogs can also regu-
late DcR3 expression in epidermal keratinocytes, especially because
the vitamin D3 analog has been reported to inhibit EGFR expression in
epidermal keratinocytes [17].
Our previous work demonstrated that DcR3 could induce angio-
genesis through neutralizing TL1A expressed by endothelial cells,
and implied that DcR3 produced by cancer cells could promote cancer
progression via angiogenic processes [33]. Another important ﬁnding
in our immunohistochemical study shown in Fig. 1 is the obvious de-
tection of DcR3 in the endothelial cells of vessels in the upper dermis,
but not the lower dermis, in psoriasis. As reported, prominent inﬂam-
mation and active angiogenesis are usually limited to the upper der-
mis [8]. In psoriasis, elongated capillaries can reach the papillary
dermis near the overlying thinning suprapapillary epidermis [2].
Thus, it is reasonable to hypothesize that DcR3 may also be in-
volved in the pathogenesis of psoriasis via promoting angiogenesis.
It is tempting to speculate that DcR3 expressed by keratinocytes
may enhance the upward growth of new vessels into the papillary
dermis near the skin surface because the induction of HUVEC mi-
gration by DcR3 has been shown in our previous study [33]. In
the report on Crohn's disease [26], prominent expression of DcR3
is also found in the endothelial cells of vessels in active lesions,
suggesting that endothelial cells can produce DcR3 in some condi-
tions. In this respect, our data revealing the ability of human endo-
thelial cells to release DcR3 upon TNF-α stimulation (Fig. 6)
support this notion.
1547N.-L. Wu et al. / Biochimica et Biophysica Acta 1832 (2013) 1538–1548In summary, we demonstrate up-regulated expression of DcR3 in
the serum and lesional skin of psoriasis. EGFR signaling plays a central
role in modulating DcR3 expression in keratinocytes. Furthermore,
inﬂammatory cytokines, especially TNF-α, can induce DcR3 expres-
sion in keratinocytes and endothelial cells, which may further con-
tribute to the progress of psoriatic skin lesions.
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